Oct 07,2021

ASCENSIA DIABETES CARE LAUNCHES THE “THIS IS DIABETES” COMPETITION TO HIGHLIGHT THE NEED FOR ACCESS TO DIABETES CARE IN SUPPORT OF IDF’S WORLD DIABETES DAY

Today Ascensia Diabetes Care, makers of the CONTOUR® Blood Glucose Monitoring system portfolio and distributors of the Eversense® Continuous Glucose Monitoring system, has launched its “This is Diabetes” art and photography competition as the company’s initiative to support World Diabetes Day. The competition is designed to use art and photography to highlight the importance of Access to Diabetes Care, in particular medication, technology, care, support, nutrition and exercise, which is the official theme chosen by the International Diabetes Federation (IDF) for 2021.

View Analyst & Ambassador Comments
Go to original news
Jun 28,2022

FDA Approved Device in 2022 | TaiDoc

Based on the customer’s demands, and market trend that Taidoc have submitted cholesterol parameter to FDA and now gratefully to announce that it has passed FDA Class II with 510(k) in June 2022.

REGULATORY FDA

#cgm

View Analyst & Ambassador Comments
Go to original news
Oct 07,2021

Twin Health Raises $140Million Series C To Scale Its Groundbreaking Whole Body Digital Twin Service Enabling Reversal And Prevention Of Chronic Metabolic Disease

Twin Health (provider of metabolic disease solutions), makers of the Whole Body Digital Twin precision health service, announced $140 million in Series C funding as it scales its service in the U.S. and globally.

FUNDING SERIES C
View Analyst & Ambassador Comments
Go to original news
Oct 07,2021

MSU Health Care Launches Clinician-led Remote Monitoring Services to Patients Across the State

MSU Health Care now offers remote monitoring to patients with health conditions like diabetes, hypertension, obesity, high cholesterol and heart disease through a partnership with Higi Care Everyday, powered by Assure Health. Higi Care Everyday is a digital health solution that helps patients and providers stay connected and ensures patients receive the care they need, when they need it. Participating patients will receive a free set of devices for at-home use. Credentialed clinicians will monitor their health data on an ongoing basis, reaching out regularly if their numbers indicate a potential issue.

PRODUCT

#rpm

View Analyst & Ambassador Comments
Go to original news
Oct 07,2021

DarioHealth Announces Agreement with Global Employer for Metabolic and Musculoskeletal Health Solutions

DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today an agreement with a global company based in the United States ("Company") to provide its integrated digital health management solution for diabetes, hypertension, and musculoskeletal (MSK) health. The contract is expected to launch in the first quarter of 2022.

PRODUCT

#dtx

#coaching

View Analyst & Ambassador Comments
Go to original news
Oct 09,2021

Manufacturers Need to Assess Rather Than Ignore User Complaints About Their Diabetes Devices

Setford and coworkers recently reported on a postmarket surveillance assessment of the LifeScan glucose meter.1 I had previously commented that while such assessments are valuable, they should also include a summary of adverse events from the FDA MAUDE (Manufacturer And User Facility Device Experience) database.2 The LifeScan authors comment about their post market surveillance study: “This program supports a growing demand by regulators for real-world evidence demonstrating consistent in-market product efficacy as opposed to the current largely passive approach that relies on assessment of reports filed by device users.”

CLINICAL STUDY

#bgm

View Analyst & Ambassador Comments
Go to original news
Oct 09,2021

Patient Demographics and Clinical Outcomes Among Type 1 Diabetes Patients Using Continuous Glucose Monitors: Data From T1D Exchange Real-World Observational Study

The benefits of Continuous Glucose Monitoring (CGM) on glycemic management have been demonstrated in numerous studies; however, widespread uptake remians limited. The aim of this study was to provide real-world evidence of patient attributes and clinical outcomes associated with CGM use across clinics in the U.S. based T1D Exchange Quality Improvement (T1DX-QI) Collaborative.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Oct 11,2021

GlucoMe and Merck to Present Digital Diabetes Management Outcomes at the Upcoming IDF Congress 2019 in South Korea

GlucoMe, the creators of an innovative digital diabetes platform, announced today that they will present the results of their digital diabetes management project at the International Diabetes Federation’s upcoming Congress in December 2019 in South Korea. The study, which was conducted in collaboration with Merck, highlights the added value of GlucoMe’s diabetes solution which helped patients reduce their HbA1c levels in only 12 weeks.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Oct 11,2021

Apollo Sugar Case Study: Setting A New Standard in Remote Diabetes Care

GlucoMe helped Apollo Sugar – part of the Apollo Hospital Group, and one of the leading healthcare outcomes and wellness company in India – holistically manage chronic diabetes patients beyond the clinic.

View Analyst & Ambassador Comments
Go to original news
Oct 12,2021

Sweetch Adds Global Digital and Remote Health Trailblazer Prof. Joseph Kvedar as New Advisory Board Member

Sweetch, a digital therapeutics innovator and creator of the hyper-personalized engagement platform for chronic conditions, announced today that Prof. Joseph Kvedar has joined its advisory board. Prof. Kvedar brings a deep understanding of remote health, digital therapeutics, and reimbursement to Sweetch, and will focus on accelerating the commercial rollout and demonstrated positive clinical impact of the company's hyper-personalized platform, as well as building connections with strategic partners to further the company's success.

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES